Browsing restrictions can be lifted for a fee.
MARX Biotech Co., Ltd engages in the online retail of men's health and cosmeceutical products. The company was founded in 2016 and is based in New Taipei City, Taiwan.
The most recent financial report for 火星生技* (7731) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7731's short-term business performance and financial health. For the latest updates on 7731's earnings releases, visit this page regularly.
According to the latest financial report, 火星生技* (7731) reported an Operating Profit of -34.99M with an Operating Margin of -11.33% this period, representing a growth of 24.69% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 火星生技* (7731) announced revenue of 308.92M, with a Year-Over-Year growth rate of 44.17%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 火星生技* (7731) held Total Cash and Cash Equivalents of 22.46M, accounting for 0.03 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 火星生技* (7731) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.02%%, operating margin of -11.33%%, and net margin of -12.31%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7731's profit trajectory and future growth potential.
According to the past four quarterly reports, 火星生技* (7731)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.08. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
火星生技* (7731)'s Free Cash Flow (FCF) for the period is 9.54M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 27.45% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
7731
火星生技*
-6.17%
(-0.06)